My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 169

    1.

    Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).

    Pyörälä K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, Pedersen TR, Kjekshus J; Scandinavian Simvastatin Survival Study (4S).

    Diabetes Care. 2004 Jul;27(7):1735-40.PMID: 15220255 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

    Pyŏrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G.

    Diabetes Care. 1997 Apr;20(4):614-20. Erratum in: Diabetes Care 1997 Jun;20(6):1048. PMID: 9096989 [PubMed - indexed for MEDLINE]Related articles

    3.

    Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

    Miettinen TA, Pyörälä K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, Berg K, Pedersen T, Kjekshus J.

    Circulation. 1997 Dec 16;96(12):4211-8.PMID: 9416884 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

    Arca M.

    Drugs. 2007;67 Suppl 1:43-54. Review.PMID: 17910520 [PubMed - indexed for MEDLINE]Related articles

    5.

    Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

    Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J.

    Circulation. 2001 Dec 18;104(25):3046-51.PMID: 11748098 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

    Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J; 4S Group.

    Lancet. 2004 Aug 28-Sep 3;364(9436):771-7.PMID: 15337403 [PubMed - indexed for MEDLINE]Related articles

    7.

    Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

    Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ.

    Circulation. 1998 Apr 21;97(15):1453-60.PMID: 9576425 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

    [No authors listed]

    Lancet. 1994 Nov 19;344(8934):1383-9.PMID: 7968073 [PubMed - indexed for MEDLINE]Related articles

    9.

    Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

    Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K.

    Arch Intern Med. 1999 Dec 13-27;159(22):2661-7.PMID: 10597756 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).

    Kjekshus J, Pedersen TR.

    Am J Cardiol. 1995 Sep 28;76(9):64C-68C.PMID: 7572690 [PubMed - indexed for MEDLINE]Related articles

    11.

    MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

    Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group.

    Lancet. 2003 Jun 14;361(9374):2005-16.PMID: 12814710 [PubMed - indexed for MEDLINE]Related articles

    12.

    Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

    Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators.

    Lancet. 2006 Sep 9;368(9539):919-28.PMID: 16962881 [PubMed - indexed for MEDLINE]Related articles

    13.

    Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.

    Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyörälä K, Wedel H.

    Am J Cardiol. 2000 Aug 1;86(3):257-62.PMID: 10922429 [PubMed - indexed for MEDLINE]Related articles

    14.

    Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.

    Wilhelmsen L, Pyörälä K, Wedel H, Cook T, Pedersen T, Kjekshus J.

    Eur Heart J. 2001 Jul;22(13):1119-27.PMID: 11428852 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

    Girman CJ, Rhodes T, Mercuri M, Pyörälä K, Kjekshus J, Pedersen TR, Beere PA, Gotto AM, Clearfield M; 4S Group and the AFCAPS/TexCAPS Research Group.

    Am J Cardiol. 2004 Jan 15;93(2):136-41.PMID: 14715336 [PubMed - indexed for MEDLINE]Related articles

    16.

    Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions.

    Heart Protection Study Collaborative Group.

    J Vasc Surg. 2007 Apr;45(4):645-654; discussion 653-4.PMID: 17398372 [PubMed - indexed for MEDLINE]Related articles

    17.

    High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

    Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.

    JAMA. 2005 Nov 16;294(19):2437-45. Erratum in: JAMA. 2005 Dec 28;294(24):3092. PMID: 16287954 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    A systematic review and economic evaluation of statins for the prevention of coronary events.

    Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

    Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.PMID: 17408535 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Lipid-lowering drug use and cardiovascular events after myocardial infarction.

    Klungel OH, Heckbert SR, de Boer A, Leufkens HG, Sullivan SD, Fishman PA, Veenstra DL, Psaty BM.

    Ann Pharmacother. 2002 May;36(5):751-7.PMID: 11978147 [PubMed - indexed for MEDLINE]Related articles

    20.

    Primary cardiovascular events and serum lipid levels in elderly Japanese with hypercholesterolemia undergoing 6-year simvastatin treatment: a subanalysis of the Japan lipid intervention trial.

    Horiuchi H, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H; J-LIT Study Group.

    J Am Geriatr Soc. 2004 Dec;52(12):1981-7.PMID: 15571531 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity